Information, not a decision

Neuroendocrine tumours: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 13 Nov 2026

Open trials (262)

NCT04665739	Phase 2	Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors	Recruiting
NCT07707895	Phase 1/2	DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers	Recruiting
NCT06406465	Phase 2	A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity	Recruiting
NCT01174121	Phase 2	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer	Recruiting
NCT04907643	No phase	Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	Recruiting
NCT03866382	Phase 2	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	Recruiting
NCT05058651	Phase 2/3	Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung	Recruiting
NCT07080242	Phase 1	Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors	Recruiting
NCT06228066	Phase 2	Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)	Recruiting
NCT07783477	Phase 1	A Study of Armored CAR T Cells in People With Cancer	Recruiting
NCT05691465	Phase 2	Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells	Recruiting
NCT06345079	Phase 2	Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours	Recruiting

250 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

No phase 3 trial in this list ended in the last 90 days.

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 13 Nov 2026

https://frontlightresearch.com/en/doctor/neuroendocrine-tumors/tumor-board